Published on January 21, 2013 at 2:11 AM
"This newly established partnership enables us to work together with one of the most prominent leaders in the field of regenerative medicine in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons" said Dr. Fredrik Ollila , CEO of BonAlive Biomaterials Ltd. "The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone".
"The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone regeneration portfolio now also in the treatment of fractures and non-unions in patients with chronic infections. During our thorough global assessment of different technologies and options we were impressed by the clinical evidence and clinical data available for BonAlive®. We are very much convinced to have decided for a partnership with the company having the right approach to improve patient outcome" said Florian Kemmerich , President of Olympus Biotech International.
SOURCE BonAlive Biomaterials Ltd